Antisense Oligonucleotide Exon Skipping for ALS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) linked to SOD1 mutations have limited therapeutic efficacy, with previous methods achieving only a maximum 38% increase in survival, and there is a challenge in delivering therapeutic agents across the blood-brain barrier to affect all affected cells.
Innovation Solution
Administration of an antisense oligonucleotide specifically designed to induce exon-skipping in human SOD1 pre-mRNA, leading to the degradation of SOD1-coding mRNA, using AAV vectors for efficient delivery across the blood-brain barrier, potentially increasing survival by up to 134%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If RNase H-dependent 2'-MOE gapmer AONs or RNAi/shRNA strategies are used to reduce SOD1 levels, then SOD1 mRNA and protein levels are reduced by 25-50%, but survival extent is limited to a maximum of 38%
Solution Approach 1:
The patent changes the molecular mechanism parameter from RNase H-dependent decay or RNAi to nonsense-mediated decay (NMD) pathway activation through exon skipping. This parameter change in the degradation mechanism results in more effective reduction of toxic SOD1 protein levels and achieves survival extent of up to 134%, surpassing previous strategies that achieved maximum 38% survival extension.
2Area of stationary object
If therapeutic agents are delivered systemically to cross the blood-brain barrier, then widespread delivery to CNS and peripheral cells is achieved, but delivery efficiency and therapeutic efficacy are limited
Solution Approach 1:
The patent uses a composite delivery system combining adeno-associated virus (AAV) vectors with chemically modified oligonucleotides (2'-O-methyl, phosphorothioate modifications). This composite approach enables efficient crossing of the blood-brain barrier while maintaining therapeutic efficacy, achieving widespread delivery to CNS and peripheral cells with survival extent of up to 134%.
3Quantity of substance
If exon skipping is induced in SOD1 pre-mRNA, then degraded mRNA is produced, but delivery across the blood-brain barrier remains challenging
Solution Approach 1:
The patent employs AAV vectors as intermediary carriers to deliver the exon-skipping oligonucleotides across the blood-brain barrier. The AAV vector acts as a mediator that protects the oligonucleotide from degradation and facilitates its entry into CNS and peripheral cells, enabling effective induction of exon skipping and degradation of SOD1 mRNA with survival extent of up to 134%.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method achieves a significant increase in survival of ALS mice by up to 134%, surpassing previous treatments, demonstrating a more effective molecular approach for SOD1-linked ALS through targeted exon-skipping and widespread gene delivery.
Implementation Method 1
administration of an antisense oligonucleotide specifically designed to induce exon-skipping in human SOD1 pre-mRNA
Implementation Method 2
leading to the degradation of the skipped mRNA by the cell machinery
Implementation Method 3
using AAV vectors for efficient delivery across the blood-brain barrier
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.